Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPN-821 · 1 trial · 1 indication
MADRS is a 10-item scale (Reported sadness, Apparent sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimist thoughts, and Suicidal thoughts) where each item is scored from 0 to 6. The total score is the sum of the 10 items ranging from 0 to 60 where higher scores indicate more severe depression, and lower scores are better outcomes.
| Arm | Type | Description |
|---|---|---|
| SPN-821 2400 mg | EXPERIMENTAL | Three 800 mg oral tablets administered twice a week adjunctive to current antidepressant |
| Placebo | PLACEBO_COMPARATOR | Three oral tablets administered twice a week adjunctive to current antidepressant |
| Name | Type | Description |
|---|---|---|
| SPN-821 2400 mg | DRUG | SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling |
| Placebo | DRUG | Matched placebo oral tablets |
Inclusion Criteria: * Current diagnosis of MDD according to the DSM-5 for either single or recurrent MDE without psychotic features confirmed by the MINI * Duration of current MDE of at least 8 weeks * MADRS total score of ≥ 24 at the Screening Visit and Day 1 Visit * CGI-S score of ≥ 4 (moderately...
Top 20 of 29 competitors
SPN-821 is an investigational small molecule being developed for the treatment of Major Depressive Disorder (MDD). It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied in adults with MDD in a randomized, double-blind, placebo-controlled trial.
SPN-821 is being developed by Supernus Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SUPN. The company is conducting a Phase 2 clinical trial of SPN-821 in adults with Major Depressive Disorder in the United States.
SPN-821 is in Phase 2 clinical development. It is currently being evaluated in a randomized, double-blind, placebo-controlled study in adults with Major Depressive Disorder. The drug is investigational and has not yet received FDA approval.
SPN-821 is being studied in a Phase 2 clinical trial with the identifier NCT07226661. This is a double-blind, placebo-controlled study in adults with Major Depressive Disorder, with an enrollment target of 230 participants. The trial is currently recruiting participants in the United States.
Yes, SPN-821 is also known as SPN-821 2400 mg, which refers to the 2400 mg dose strength of the drug. The drug is being developed by Supernus Pharmaceuticals for the treatment of Major Depressive Disorder and is currently in Phase 2 clinical trials.